Shares of Cytosorbents Corp. (CTSO) are soaring over 35% in pre-market today, after the company announced that CytoSorb is now specifically recommended in the Italy Brescia Renal COVID Task Force Guidelines to treat patients with severe COVID-19 infection and Stage 3 renal failure on continuous renal replacement therapy (CRRT), published last week on the Italian Society of Nephrology website.
from RTT - Before the Bell https://ift.tt/2Jg5ALS
via IFTTT
No comments:
Post a Comment